InternationalUSRemember you can easily switch between MIP US and MIP International at any time

Comments on India’s draft biotech patent guidelines posted

Peter Leung, Hong Kong


The India Patent Office has released public feedback to its draft guidelines for the examination of biotechnology patents

The guidelines were released on December 11 2013 with a public comment period until January 11. The Patent Office received comments from Indian biotechnology firms, patent law firms, and groups such as the Organisation of Pharmaceuticals Producers of India (OPPO), the Biotechnology Industry Organization (BIO) and even the Japan Intellectual Property...


Please log in to read the rest of this article.

New to Managing Intellectual Property? Take advantage of one week’s FREE access and become a Managing IP member today. It’s free to join and the benefits start straight away.

Already registered?

Please make sure you log in to read the rest of the article.

Log in

Join us now

Gain 7 days FREE access when you register now.

Join here

profile

Managing IP

ManagingIP

ManagingIP profile

Tube chat: The new badge encouraging commuters to talk to each other https://t.co/2qiElj3GUo Is this an infringing use of the LU roundel TM?

Sep 29 2016 10:53 ·  reply ·  retweet ·  favourite
ManagingIP profile

Latest IP moves in Americas incl. @dla_pipercanada @BrooksKushman @WhiteCase @FishRichardson @bakerbotts https://t.co/AAGdzufBMV ($/trial)

Sep 29 2016 10:46 ·  reply ·  retweet ·  favourite
ManagingIP profile

Interesting patent infringement case in China over ODD motors https://t.co/QtS5MZGeVN

Sep 29 2016 10:37 ·  reply ·  retweet ·  favourite
More from the Managing IP blog


Read this year's AIPPI Congress News - published daily by Managing IP direct from the AIPPI Annual Meeting in Milan


null null null

October 2016

10 issues to watch at the PTAB

Last month marked the fourth anniversary of Patent Trial and Appeal Board proceedings becoming available. While early cases suggested that the Board would be a graveyard for patents, in the past year a more nuanced picture has emerged. Michael Loney identifies 10 issues to watch



Most read articles

Supplements